Brain Cancer

Metastatic Breast Cancer

Breast Cancer

Colorectal Cancer

Gastric Cancers

Liver Cancer

Gastrointestinal Cancer

Bladder Cancer

Kidney Cancer

Prostate Cancer

Genitourinary Cancer

Cervical Cancer

Endometrial Cancer

Ovarian Cancer

Gynecologic Cancers

Head and Neck Cancers

Graft-Vs-Host Disease

Leukemia

Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Hematology

Lung Cancer

Pediatric Cancer

Sarcomas

Melanoma

Skin Cancer

Michael Lai, ARNP, explained the mechanism of action of PARP inhibitors for the treatment of patients with prostate cancer.

Understanding the Mechanism of Action Behind PARP Inhibitors for Prostate Cancer

The Immune Effector Cell Encephalopathy score and keeping a close eye on patients’ symptoms are critical when monitoring for potential ICANS during lymphoma treatment.

Tools to Monitor for ICANS During Lymphoma Treatment With Bispecific Antibodies, CAR T-Cell Therapy

A multidisciplinary approach to adverse effect management addresses many needs patients with gynecologic cancers may have while undergoing treatment. 

‘Bringing Every Single Resource’ When Caring for Patients Receiving Treatment for Gynecologic Cancers

Applying diversity, equity, and inclusion to cancer clinics can help oncology nurses and APPs make an impact on patient care and research. 

Bringing DEI to Clinical Trial, Cancer Clinics Through Self-Awareness

News

Latest News

FDA News

Adverse Event Management

Supportive Care

Disparities in Cancer Care

Drug Safety

Radiation Oncology

Survivorship 

Practice Management

Prevention

Contributors

Media

Expert Connections

Morning Rounds

The Vitals

Podcasts

Videos

Between the Lines

Conferences

Conference Coverage

Conference Listing

Publications

CME/CE

Continuing Education

Resources

Case-Based Digest 

Rx Road Map

Webinars

Cancer Summary Slides

MPN Symptom Management

Events

Subscribe

Partners

Articles

Kristi Rosa joined MJH Life Sciences in 2016 and has since held several positions within the company. Prior to working at the company, she served as lead copywriter and marketing coordinator at The Strand Theater. Email: krosa@onclive.com

Companion diagnostics have been approved by the FDA for olaparib plus abiraterone in patients with metastatic castration-resistant prostate cancer.

Companion Diagnostics for Olaparib Plus Abiraterone Acetate Gains FDA Approval in BRCA+ mCRPC

Adjuvant trastuzumab reveals associations with improved disease-free survival in 1-year vs 9-week administration of the drug in patients with ERBB2-positive breast cancer. 

Longer Duration of Adjuvant Trastuzumab May Further Improve DFS Rates in ERBB2-Positive Breast Cancer 

The FDA approved Boruzu, a new presentation of bortezomib, for subcutaneous or intravenous administration in patients with multiple myeloma and mantle cell lymphoma.

Bortezomib Injectable Receives FDA Approval for Multiple Myeloma and MCL

This retrospective review demonstrates the increased use of active surveillance in patients with small nonfunctional pancreatic neuroendocrine tumors. 

Active Surveillance May Benefit Certain Patients With Small Nonfunctional Pancreatic NETs

CancerNetwork.com

CureToday.com

OncLive.com

TargetedOnc.com

Advertise

Privacy

Terms & Conditions

Do Not Sell My Information

Oncology Nursing News

Facebook

Twitter

LinkedIn

Specialty

Advanced Practice Providers

Clinical

Gynecologic Cancer

Immunotherapy

Nurse Navigation

Quality Improvement

1rem

Bintrafusp alfa induced responses in recurrent/metastatic cervical cancer, supporting the need for further research into TGF-β-targeted therapies.

Bintrafusp Alfa Elicits Responses in Post-Platinum Recurrent or Metastatic Cervical Cancer

A breakthrough device designation has been granted by the FDA to Teal Wand, an at-home screening test for cervical cancer.

Cervical Cancer Test Receives Breakthrough Device Designation from FDA

HPV vaccines in patients under the age of 40 may have lowered rates of HPV-related cancer compared with unvaccinated patients.

HPV Vaccinations Lowered HPV-Caused Cancers Rates in Patients Under the Age of 40

One of the first HPV self-collection solutions has been approved by the FDA, which can identify women at risk of developing cervical cancer.

HPV Self-Collection Test for Cervical Cancer Receives FDA Approval

The FDA has approved tisotumab vedotin-tftv for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.

Tisotumab Vedotin-tftv Approved by FDA in Advanced Cervical Cancer

Cervical Cancer

Latest News

Latest Conference Coverage